Trial Profile
(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms OSKIRA-Asia-1
- Sponsors AstraZeneca
- 30 Nov 2020 Results published in the Rheumatology
- 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.(Parent trial: NCT01569074).